Anavex Life Sciences (AVXL) Operating Expenses (2016 - 2025)

Anavex Life Sciences' Operating Expenses history runs 10 years deep, the most recent figure standing at $6.8 million for Q4 2025.

• In Q4 2025, Operating Expenses fell 50.1% year-over-year to $6.8 million; the TTM figure through Dec 2025 stood at $44.6 million (down 19.05% YoY), while the FY2025 annual figure was $51.4 million, down 2.78% from the prior year.
• Operating Expenses came in at $6.8 million for Q4 2025 at Anavex Life Sciences, down from $10.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $15.4 million in Q4 2022 to a low of $6.8 million in Q4 2025.
• A 5-year average of $12.5 million and a median of $12.6 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 122.41% in 2021 and sank 50.1% in 2025, its largest moves.
• Anavex Life Sciences' Operating Expenses stood at $11.7 million in 2021, then jumped by 31.22% to $15.4 million in 2022, then retreated by 26.04% to $11.4 million in 2023, then gained by 19.46% to $13.6 million in 2024, then tumbled by 50.1% to $6.8 million in 2025.
• According to Business Quant data, Operating Expenses over the past three periods registered $6.8 million, $10.8 million, and $14.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison